Verge Genomics

OverviewSuggest Edit

Verge Genomics is a biopharmaceutical company using systems biology to accelerate the development of treatments for neurodegenerative diseases. Its platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets and predict effective drugs.
TypePrivate
Founded2015
HQSouth San Francisco, CA, US
Websitevergegenomics.com

Latest Updates

Employees (est.) (Jun 2022)49(+23%)
Job Openings14
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Verge Genomics

Alice Zhang

Alice Zhang

Chief Executive Officer and Co-Founder
Jane Rhodes

Jane Rhodes

Chief Business Officer
Victor Hanson-Smith

Victor Hanson-Smith

Head of Computational Biology
Rob Scannevin

Rob Scannevin

Chief Science Officer
Ben Jackson

Ben Jackson

Vice President of Operations and Finance
Irene Choi

Irene Choi

Senior Director and Head of Drug Discovery
Show more

Verge Genomics Office Locations

Verge Genomics has an office in South San Francisco
South San Francisco, CA, US (HQ)
2 Tower Pl
Show all (1)

Verge Genomics Financials and Metrics

Summary Metrics

Founding Date

2015

Verge Genomics total Funding

$36.1 m

Verge Genomics latest funding size

$32 m

Time since last funding

4 years ago

Verge Genomics investors

Verge Genomics's latest funding round in July 2018 was reported to be $32 m. In total, Verge Genomics has raised $36.1 m
Show all financial metrics

Verge Genomics Operating Metrics

May, 2020

Partners

29

Verge Genomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Verge Genomics Online and Social Media Presence

Embed Graph

Verge Genomics News and Updates

Verge Genomics Inks Multi-Million Dollar Deal With Lilly To Discover New ALS Drugs

The 30 Under 30 company will receive $25 million upfront from Lilly with a potential of almost $700 million and drug royalties.

How Verge Genomics Uses AI To Tackle Parkinson’s, Alzheimer’s And ALS

Using a combination of machine learning and proprietary data, CEO Alice Zhang is looking to develop more powerful treatments for neurodegenerative disease.

AI drug discovery startup Verge Genomics raises $32 million

Silicon Valley startup Verge Genomics, which uses AI to accelerate drug discovery, has raised $32 million in a funding round.

Verge Genomics Frequently Asked Questions

  • When was Verge Genomics founded?

    Verge Genomics was founded in 2015.

  • Who are Verge Genomics key executives?

    Verge Genomics's key executives are Alice Zhang, Jane Rhodes and Victor Hanson-Smith.

  • How many employees does Verge Genomics have?

    Verge Genomics has 49 employees.

  • Who are Verge Genomics competitors?

    Competitors of Verge Genomics include E-Scape Bio, American Life Science Pharmaceuticals and Alector.

  • Where is Verge Genomics headquarters?

    Verge Genomics headquarters is located at 2 Tower Pl, South San Francisco.

  • Where are Verge Genomics offices?

    Verge Genomics has an office in South San Francisco.

  • How many offices does Verge Genomics have?

    Verge Genomics has 1 office.